A novel anti-CTLA-4 nanobody-IL12 fusion protein in combination with a dendritic cell/tumour fusion cell vaccine enhances the antitumour activity of CD8+ T cells in solid tumours
Our in vitro and in vivo results suggest the anticancer potential of our nanobody-interleukin fusion system and support the clinical application of this fusion approach for various nanobodies.
Authors
- A. Q. Liu (ORCID: https://orcid.org/0000-0002-0126-5778)
- Haiyan Cui (ORCID: https://orcid.org/0000-0003-4969-4835)
- Xiaoling Lü (ORCID: https://orcid.org/0000-0001-9049-2077)
- Tingting Li (ORCID: https://orcid.org/0000-0002-1829-0267)
- Xiaomei Yang (ORCID: https://orcid.org/0000-0002-4081-4207)
- Mengjie Jiang (ORCID: https://orcid.org/0000-0002-5659-7163)
Institutions
- Guangxi Medical University (CN)
Publication Details
- Journal
- Journal of Nanobiotechnology
- Published
- 2024-10-19
- DOI
- https://doi.org/10.1186/s12951-024-02914-6
- Citations
- 5
- Primary Topic
- Immunotherapy and Immune Responses
- Type
- article
- Field-Weighted Citation Impact
- 1.20
Funders
- National Natural Science Foundation of China
- Natural Science Foundation of Guangxi Province